Bristol Myers Squibb’s schizophrenia drug Cobnefy failed to meet a primary goal in a phase 3 trial, possibly clouding the drug’s future development.
The trial evaluated Cobnefy as an add-on therapy to existing atypical antipsychotics in adults with uncontrolled schizophrenia symptoms, according to an April 22 news release from the drugmaker.
After six weeks, patients receiving Cobnefy, along with an atypical antipsychotic, saw a 14.3-point reduction in the positive and negative syndrome scale score, compared to a 12.2-point reduction in the placebo group. As a result, the 2.0 difference did not reach statistical significance.
Secondary endpoints also showed no significant statistical differences, including changes in personal and social performance scores and clinical impressions severity scores.
The company plans to do a complete evaluation and share results at a future medical conference, the release said.
